Abstract 545P
Background
Immune checkpoint inhibitors (ICI) are standard of care in advanced non-small cell lung cancer (NSCLC) without driver mutations. A small proportion of patients (pts) treated with ICIs will achieve durable responses. We describe outcomes of a real-world cohort of pts who completed two years of pembrolizumab (pembro).
Methods
Clinical data of pts who completed 35 cycles of first-line pembro for NSCLC (or 30-34 cycles with reason for cessation other than progression) was collected retrospectively from sites across Australia via the AUstralian Registry and biObank of thoRacic cAncers (AURORA). Primary endpoints were progression rate post pembro completion and progression free survival (PFS). Local treatment of oligoprogressive disease during pembro was included. Analyses were performed using R.
Results
71 pts from six centres with a median age of 66.0 yrs, 49% male & 90% ECOG≤1 were identified. Pts were Caucasian (82%) or Asian (16%); past (69%) or current (25%) smokers with a mean 37 pack year history. Histology comprised 73% adenocarcinoma, 16% squamous. 18 pts (25%) had brain mets at diagnosis, 16 treated (8 resected, 8 RT). Median PD-L1 tumour proportion score (TPS) was 68%; 12 pts (17%) PD-L1 negative, 43 pts (61%) TPS≥50%. No pts had ALK/ROS/EGFR mutations; 29/49 tested (60%) had K-Ras mutations. Median follow up from pembro start was 38.7 months (24.5 – 65.6). Table: 545P
Total population (n=71) | |||
Pembro | 39 (55%) | Median time on pembro | 24.2 mo |
Pembro + chemo | 32 (45%) | (20.0-35.3) | |
Objective Response Rate (ORR) | 78.6% | 76.9% | |
CR | 20 (29%) | ORR pembro | 80.6% |
PR | 35 (50%) | ORR pembro+chemo | p=0.86 |
Median PFS | 46.1 mo (95%CI 39.5-NR) | PFS in PD-L1≥1%PFS in PD-L1 neg | NR (46.1-NR)28.1 mo (16.3-NR)p=0.013 |
Oligoprogression during pembro | |||
Total | 17 (24%) | ||
Locoregional | 8 | PFS oligo subgroup | 12.0 mo (9.4-18.9) |
Brain | 7 | PFS2 | 23.1 mo (20.2-NR) |
Progression post pembro | |||
Total | 20 (28%) | Median time to progression | 3.3 mo (1.0-26.3) |
Locoregional | 11 | ||
Brain | 3 | ||
Bone | 5 | ||
PD-L1≥1% | 13 | Pts with CR | 2 |
PD-L1 neg | 6 (OR 3.46, p=0.06) | Pts without CR | 18 (OR 5.06, p=0.04) |
Brain mets at diagnosis (n=18) | |||
CNS progression | 6 (33%) |
Conclusions
Pts completing two years of pembro for NSCLC in Australia had high rates of K-Ras mutation and PD-L1 expression; a significant proportion had brain metastases and treated oligoprogression. Progression rate post pembro was higher in PD-L1-negative pts and in those without complete response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AURORA (AUstralian Registry and biObank of thoRacic cAncers) national database. Each participating hospital in various sites throughout Australia had ethics approval to contribute to the AURORA database via their local ethics committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract